R&D / revenue moved 39979 bp lower
R&D / revenue changed -39979 basis points from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
R&D / revenue changed -39979 basis points from the comparable as-filed period.
Capital expenditure changed -54.7% from the comparable as-filed period.
Operating cash-flow margin changed +48822 basis points from the comparable as-filed period.
Free-cash-flow margin changed +49307 basis points from the comparable as-filed period.
Current ratio changed +13.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Working capital / assets changed -70 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
R&D / revenue changed +411122 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash-flow margin changed -539382 basis points from the comparable as-filed period.
Free-cash-flow margin changed -541889 basis points from the comparable as-filed period.
Current ratio changed +16.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital / assets changed -36 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.